Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyone have an idea what that 270 million will be spent on? I can't imagine it costs that much to create a US subsidiary:
"Wuhan Humanwell Healthcare will acquire Epic Pharma, a New York state generic drug manufacturer, for $550 million. In a brief announcement, Humanwell said it would invest $270 million to create a US subsidiary, which would then own Epic. Formed in 2008, Epic bought a generic drug manufacturing previously owned by Sandoz. It produces a number of generic drugs and provides contract manufacturing services. In 2015, Epic said its revenues exceeded $120 million per year."
Let's not forget the barriers to entry in the Chinese market:
I love this article which gives you insight into what's brewing in China regarding biotech:
http://www.chinabiotoday.com/articles/20160414
“There is a lot of money flowing and the amounts are going up exponentially,” he said.
“To enter the Chinese market, you may come in by licensing an asset, which we have done, or you can create a joint venture, which we have also done. But you cannot go in by yourself.”
Keyoung described different options including what he called a WOFE, a wholly foreign-owned enterprises that is an investment vehicle for mainland China. With either a joint venture or a WOFE, he said, a foreign company can tap into the flow of government funding at the city, county or provincial level in variations on private-public investment models or more commonly through the technology parks.
I sure hope you paper trade the stocks you provide DD on. Indirect news? LMFAO
Humanwell, PuraCap Acquire Epic Pharma for $550M
Humanwell Healthcare Group and PuraCap Pharmaceutical said today they agreed to acquire Epic Pharma for $550 million.
The buyers said the deal will expand both their commercial and manufacturing capabilities, as well as their presence in the U.S. generics market.
Epic's portfolio consists of 15 marketed generic products consisting of tablets, two-piece capsules, and powder dosage form products, as well as a pipeline of 37 products that includes controlled drug substances.
Humanwell and PuraCap said the deal was designed in part to complement PuraCap's existing R&D efforts by using Epic's know-how in manufacturing and developing controlled drug substances and powder formulations.
As part of the deal, the buyers will acquire Epic’s FDA and U.S. Drug Enforcement Agency–inspected Good Manufacturing Practice (GMP) manufacturing site, a 110,000-square-foot facility in Laurelton, NY. That will add 215 employees to the Humanwell and PuraCap U.S. operations team, the companies said.
“The addition of Epic is an important addition to the PuraCap family,” Dahai Guo, CEO of PuraCap and president of Humanwell USA, said in a statement. “We look forward to it being a platform for the development of our generic pharmaceutical business, both in the USA as well as internationally."
The companies said the deal is expected to close in the scond quarter subject to customary conditions that include expiration of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act, approval of Humanwell stockholders, and registrations from certain governmental entities in China.
Chinese-based Humanwell specializes in investing, developing, and managing healthcare companies. Founded in 1993, the publicly traded company has a market capitalization of $3.5 billion.
PuraCap oversees two companies: PuraCap Pharmaceutical, focused on prescription brand-name drugs, and PuraCap International, which markets prescription generics and over-the-counter (OTC) and private-label brands.
PuraCap International, a joint venture with Dangdai International Group, was created just last week when PuraCap Pharmaceutical acquired two other companies, Blu Pharmaceutical and Blu Caribe, in a deal announced March 24.
That deal expanded PuraCap's manufacturing expertise beyond soft gelatin capsules to include oral tablet and capsule dosage forms for both the U.S. and global markets. Under the transaction, PuraCap acquired a 145,000 square-foot current GMP (CGMP) manufacturing facility in Dorado, Puerto Rico, and a 185,000 square-foot warehouse and distribution center in Franklin, KY.
Smart investors are buying thimble sized loads right Dr. L?
The real world has been very kind to me regardless of it's attempts to bring me down. These aren't self-perceived truths, everything is based on facts. For instance the comment regarding sample size. All you have to do is compare the sample sizes used for other FDA submissions to figure out what they are looking for. With a p value of .001 you'll only strengthen the argument and raise costs. There are plenty of people here that have taken advanced statistics courses that know this. The fact that I'm calling out the inconsistencies posted on this board are not unique to me. Bring the facts and let them do the talking for you.
R2 D2, or rollin2nyte due diligence
2.26% is considered barely budging in price? I'm also not sure how volume below 1 million shares is considered high. Shows how long you've been here.
Yes, can be found here: http://ir.elitepharma.com/External.asp?L=I&from=du&ID=67897&B=2258
I'm willing to bet it was during the "Data Blitz" from 6-8PM on 5/11. Think of it as a shark tank for new research.
Are you serious? That's gotta be the most blatant piece of misinformation I've ever heard on this board.
What volume are you looking at?
I agree, after seeing how exhausted the committee was for KMPH I don't think they'll bring them back for a third day in June. Early July would be cutting it too close.
Please do, I always like to fill any gaps.
So you'd prefer to invest in a stock with no page views? And that would be a huge positive???
I was awake when mine we're pulled, impacted. Novacaine was used to numb it. I would much rather be knocked out for it. Of course there are other instances where IR is preferred.
"I'm sure we'll get approval here on ELI. Competition is big here. But, with ADF's piling up to replace OxyContin well then I draw a conclusion OxyContin gets the boot by FDA and the market is up for grabs."
I couldn't agree more. That's the part of competition that Sixman doesn't understand. There's no way the FDA creates a monopoly out of a company that is first to market with a ADF product. Only when there are sufficient options for doctors to prescribe will they remove the non-ADF products from the market. This will greatly increase market share for those in play.
No kidding, look at the volume. They seem to be very active. Lack of volume is killing you guys.
Your missing the entire point of why new entrants into the market is a good thing. If you can't figure that out then you 're in the wrong investment.
And of course there are many competitors to Elite. You wanna know why? Because the modular formulation puts us in play with every subset of the ADF market.
If I had my wisdom teeth pulled I'd want the pain to stop ASAP, not 2 hours from now. Hence the term immediate release. On a more relevant note, why do you think addicts extract the opioids from ER formulations and snort/inject? Hint, it's not because they want to get high in a couple hours.
Acid, shrooms and MDMA are a different story.
You do understand the purpose of immediate release right? I mean, it's in the name.
PLEASE SHARE THE FORM 4'S TO SUPPORT THIS
Thanks for sharing!
Do you have a link that proves that millions upon millions have been dumped?
Now where does the FDA say that?
Or they are irrational, doing everything they can to drive up volume without any luck.
You might want to look up the historical volumes. We've been trading well below average since FDA NDA acceptance.
Where's the volume to support that? Insiders aren't selling and there's no institutional ownership.
I'm mostly upset I didn't get an LOL out of my bunion/foot in the door joke.
I was talking about Teva
Yeah, 20 billion for bunion trials barely gets your foot in the door!
Are you saying 2nd tier pharmacy companies cannot afford clinical trials?
Data will be presented before we can even have an advisory meeting, that's if the FDA even thinks we need one.
Conference is this week already.
He's not even correct by saying 750million. I guess with their margin of error everything constitutes and accurate prediction....
How does a $1 PPS = 1 billion dollar valuation?
I thought you guys said approval was priced in?
It's not rocket science, just add a once-a-day oxycodone bead w/ a naltrexone bead and you have a once-a-day abuse resistant product. Therefore, ELI-200 represents three products. I wonder how difficult this is to replicate with morphine?
Answer: Pretty f'in easy
I'll say this again, we're not colonizing Mars here.
And did we tell you the name of the game, boy?
We call it 'riding the gravy train' - Pink Floyd
http://biotuesdays.com/2013/08/06/elite-eyes-home-run-in-abuse-resistant-technology/
"Elite also has commercially scaled up a once-daily formulation of oxycodone, which currently doesn’t exist on the U.S. market. “I don’t think it takes a whole lot of imagination to realize that once we’ve demonstrated that we can develop an abuse-resistant formulation that’s twice-a-day, it’s not that hard to combine the once-a-day oxycodone bead with a naltrexone bead and hence you also have a once-a-day abuse-resistant formulation. So, oxycodone actually represents three products for us.”
Mr. Treppel recalls that Elite previously tried to license the once-a-day formulation in the European market and had found a partner. “At that time, we didn’t have the financial wherewithal to pursue that opportunity. It’s fair to say that that opportunity may get looked at again because there are opportunities overseas, especially the European and Asian markets for opioids.”
In addition, he says Elite is working on an abuse-resistant morphine molecule. “A non-abuse formulation and an abuse formulation are currently on the market, so that one molecule represents two product opportunities for us,” he adds.
“We’re not reinventing the wheel with every product, which is really the position that our competitors are in,” he contends. “Every time they try and develop one of these abuse-resistant opioid products, each one is unique and requires a unique approach. We don’t see it that way. We think we have a platform. We take a particular opioid molecule and develop an extended release formulation. We already have the naltrexone bead, so we put them in a capsule and we have a potential product.”
But I thought you said approval was priced in. So how can the market cap go up 100million upon approval and labeling if it's priced in?